rTMS 对2型糖尿病摄食行为及餐后血糖的影响

注册号:

Registration number:

ChiCTR2400088977 

最近更新日期:

Date of Last Refreshed on:

2024-08-29 17:01:26 

注册时间:

Date of Registration:

2024-08-29 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

rTMS 对2型糖尿病摄食行为及餐后血糖的影响

Public title:

Effects of rTMS on ingestive behavior and postprandial glucose in type 2 diabetes mellitus

注册题目简写:

English Acronym:

研究课题的正式科学名称:

rTMS 对2型糖尿病摄食行为及餐后血糖的影响

Scientific title:

Effects of rTMS on ingestive behavior and postprandial glucose in type 2 diabetes mellitus

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

于鹏龙 

研究负责人:

袁捷 

Applicant:

Yu Penglong 

Study leader:

Yuan Jie 

申请注册联系人电话:

Applicant telephone:

+86 183 9105 1357

研究负责人电话:

Study leader's
telephone:

+86 152 2924 2772

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

76193263@qq.com

研究负责人电子邮件:

Study leader's E-mail:

yuanjie8782@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

重庆市万州区百安坝天星路366号

研究负责人通讯地址:

陕西省西安市莲湖区西华门4号

Applicant address:

No. 366 Tianxing Road, Bai'anba, Wanzhou District, Chongqing, China

Study leader's address:

No.4 Xihua Gate, Lianhu District, Xi'an City, Shaanxi Province, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

重庆三峡医药高等专科学校

Applicant's institution:

Chongqing Three Gorges Medical College

研究负责人所在单位:

陕西省中医医院

Affiliation of the Leader:

Shaanxi Provincial Hospital of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

(2024)伦审第(38)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

陕西省中医医院伦理委员会

Name of the ethic committee:

Shaanxi Hospital of Traditional Chinese Medicine Ethics Committee

伦理委员会批准日期:

Date of approved by ethic committee:

2024-07-30 00:00:00

伦理委员会联系人:

史亮

Contact Name of the ethic committee:

Shi Liang

伦理委员会联系地址:

陕西省西安市莲湖区西华门4号

Contact Address of the ethic committee:

No.4 Xihua Gate, Lianhu District, Xi'an City, Shaanxi Province, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 152 2924 2772

伦理委员会联系人邮箱:

Contact email of the ethic committee:

sxszyyyllb@126.com

研究实施负责(组长)单位:

陕西省中医医院

Primary sponsor:

Shaanxi Provincial Hospital of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

陕西省莲湖区西华门4号

Primary sponsor's address:

No.4 Xihua Gate, Lianhu District, Xi'an City, Shaanxi Province, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

陕西省

市(区县):

西安市

Country:

China

Province:

Shaanxi Province

City:

Xi'an prefecture level city in Shaanxi

单位(医院):

陕西省中医医院

具体地址:

陕西省莲湖区西华门4号

Institution
hospital:

Xi'an prefecture level city in Shaanxi

Address:

No.4 Xihua Gate, Lianhu District, Xi'an City, Shaanxi Province, China

经费或物资来源:

重庆市教委科学技术研究项目

Source(s) of funding:

Scientific and Technological Research Program of Chongqing Municipal Education Commission

研究疾病:

2型糖尿病  

Target disease:

Type 2 diabetes

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

明确高频 rTMS 左额叶背外侧对 2 型糖尿病患者摄食行为、餐后血糖的影响并探索其神经机制  

Objectives of Study:

Defining the effects of high-frequency rTMS dorsolateral left frontal lobe on feeding behavior and postprandial glucose in patients with type 2 diabetes mellitus and exploring its neural mechanisms

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

①排除 1 型糖尿病或因感染、使用激素等应激性高血糖者; ②4 周内服用过其他抑制食欲药物者; ③严重的糖尿病并发症等影响疗效评估者; ④由于其他疾病因素导致的食欲亢进者; ⑤严重心脏病患者; ⑥伴有严重心血管、肝、肾、脑和造血系统等疾病、有精神疾病者; ⑦经颅磁治疗禁忌症者,如心脏起搏器、颅内金属物等; ⑧控制血糖方式非口服盐酸二甲双胍片者: ⑨不具有糖尿病典型食欲亢进症状者(VAS 评分<7 分); ⑩不接受本实验者。

Exclusion criteria:

1. Rule out type 1 diabetes or stress hyperglycemia due to infections, hormone use, etc. 2. Those who have taken other appetite suppressants within 4 weeks; 3. Those who have taken other appetite suppressants within 4 weeks; 4. Serious diabetic complications affecting the assessment of the efficacy of treatment; 5. Those with hyperphagia due to other disease factors; 6. Those with serious cardiovascular, hepatic, renal, cerebral and hematopoietic diseases, and those with mental illness. 7. People with contraindications to transcranial magnetic therapy, such as cardiac pacemakers, intracranial metal objects, and so on; 8. Those who control blood glucose in a way other than taking oral metformin hydrochloride tablets: 9. Those who do not have typical hyperphagia symptoms of diabetes mellitus (VAS score <7); 10. Those who do not accept this experiment.

研究实施时间:

Study execute time:

From 2024-08-26 00:00:00 To 2024-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-09-01 00:00:00 To 2024-12-31 00:00:00

干预措施:

Interventions:

组别:

对照组

样本量:

28

Group:

Control group

Sample size:

干预措施:

予口服盐酸二甲双胍片 0.5g,2 次/日以控制血糖

干预措施代码:

Intervention:

Metformin hydrochloride tablets 0.5g, 2 times/day was given to control blood glucose.

Intervention code:

组别:

试验组

样本量:

28

Group:

test group

Sample size:

干预措施:

对照组基础上+rTMS 左额叶背外侧 itbs1800 个脉冲,1次/日;

干预措施代码:

Intervention:

rTMS left dorsolateral frontal itbs1800 pulses 1x/day;

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

陕西省 

市(区县):

西安市 

Country:

China

Province:

Shaanxi Province

City:

Xi'an

单位(医院):

陕西省中医医院 

单位级别:

三甲 

Institution
hospital:

Xi'an prefecture level city in Shaanxi

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

午餐后 2h 血糖

指标类型:

主要指标

Outcome:

2h after lunch Glucose

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

主观食欲 VAS 评分

指标类型:

次要指标

Outcome:

Visual Analogue Score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

事件相关电位(ERP)

指标类型:

次要指标

Outcome:

event-related poten-tial

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 75 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

研究者应用 SPSS23.0 进行完全随机分组。

Randomization Procedure (please state who generates the random number sequence and by what method):

The researcher applied SPSS 23.0 to perform completely randomized grouping.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

不共享

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

not sharing

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表(CRF)

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form, CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2024-08-29 17:01:07